FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Business Insider on MSN8d
The FDA is about to make weight-loss drugs a lot harder to getLots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
The Motley Fool on MSN8d
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...
On Wednesday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback